ArticleSaudi medical journal2026
Epidemiological mapping of drug-susceptible and resistant tuberculosis in 30 WHO high-burden countries:
Article in Saudi medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Tuberculosis (TB) continues to drive infectious mortality worldwide. The study characterized the evolution of drug-susceptible TB (DS-TB), multidrug-resistant TB (MDR-TB), and extensively drug-resistant TB (XDR-TB) in 30 WHO high-burden countries, linking current patterns to long-term trends, age structure, and forward-looking scenarios to 2043. Methods: Using GBD 2023 estimates for 1990-2023, we extracted incidence, mortality, and DALYs as age-standardized rates (ASR) per 100,000 with 95% uncertainty intervals. Temporal dynamics were summarized with Estimated Annual Percent Change (EAPC) and extended linearly to 2043. GBD incidence and mortality were compared against WHO national TB series for 2010-2023. Results: Overall TB incidence ASR declined in 28/30 countries between 1990 and 2023, ranging from a 79.2% reduction in Bangladesh to a 24.9% increase in the Philippines. Mortality and DALY ASR decreased in 29/30 countries. DS-TB incidence dropped in 28/30 settings, while MDR-TB incidence rose in 28/30, from -62.5% in China to +23,603% in Kyrgyzstan. The MDR/RR-TB burden shifted toward older adults (≥55 years) in countries such as China (+22 percentage points), whereas youth contributions remained high in Nigeria (~40%). Projections assuming constant EAPC suggest continued DS-TB declines but sustained MDR-TB in Eastern Europe and Central Asia. Conclusion: The MDR-TB remains concentrated and often increasing with limited detectable XDR-TB. Age-tailored interventions, universal drug-susceptibility testing, scale-up of all-oral second-line regimens, and adherence support are critical to reverse resistant-TB trajectories while preserving gains against DS-TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.